Press Release - Company Data

SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration
Posted 2014-08-28 00:10NAI Editing
and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolization of malignant hypervascularized tumors.

SciClone Reports Financial Results for the First Quarter 2014
Posted 2014-05-12 00:03NAI Editing
today reported financial results for the first quarter ended March 31, 2014.

SciClone Reports 2013 Financial Results and 2014 Outlook
Posted 2014-03-11 23:42NAI Editing
today reported financial results for the fourth quarter and year ended December 31, 2013.

SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
Posted 2014-02-09 23:46NAI Editing
today announced the appointment of Charles Meng as General Counsel and Vice President of Compliance effective February 9, 2014. Mr.

SciClone Provides 2013 Financial Update and 2014 Guidance
Posted 2014-01-08 23:39NAI Editing
today announced its anticipated year-end 2013 cash position and provided its initial 2014 revenue guidance as follows.

SciClone Appoints Nancy T. Chang, Ph.D., to Its Board of Directors
Posted 2013-09-22 23:32NAI Editing
today announced that Nancy T. Chang, Ph.D., has been appointed a member of the Company's board of directors. Dr.

SciClone Reports Financial Results for the Three and Six Months Ended June 30, 2013 and Updates 2013 Guidance
Posted 2013-08-06 22:53NAI Editing
today reported financial results for the three and six months ended June 30, 2013, and updated guidance for 2013.

SciClone Appoints Wilson W. Cheung as Chief Financial Officer
Posted 2013-07-14 23:39NAI Editing
today announced the appointment of Wilson W. Cheung as Chief Financial Officer and Senior Vice President, Finance. Mr.

SciClone and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow(R), a Novel Treatment for Peripheral Arterial Disease for the China Market
Posted 2013-06-24 23:33NAI Editing
today announced that the Company has entered into an agreement with Taiwan Liposome Company (TLC) granting SciClone a license and the exclusive rights in China, Hong Kong and Macau to promote, market,

SciClone and Zensun Enter Into a Licensing Agreement for Novel Chronic Heart Failure Drug Neucardin(TM) for the China Market
Posted 2013-05-16 06:38NAI Editing
today announced that the Company has entered into an agreement with Zensun (Shanghai) Science & Technology Co., Ltd.